- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02019368
Antioxidant Effect of Aged Garlic Extract
August 17, 2015 updated by: Fumiko Higashikawa, Hiroshima University
A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Antioxidant Effect of Aged Garlic Extract in Heavy Smokers
This is a randomized, double-blind, placebo controlled, crossover study to determine the antioxidant effect of aged garlic extract.
This study will also compare the oxidative status in heavy smokers with that in non-smokers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hiroshima, Japan, 734-8551
- Hiroshima University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Smoking (at least 20 cigarettes per day) or non-smoking (more than 20 years)
Exclusion Criteria:
- Under medication for chronic disease
- Garlic allergy
- Engaging in vigorous exercise
- Taking drugs or functional food that may possess antioxidant property
- Participation in any clinical trial within 90 days of the commencement of the trial
- Renal or hepatic dysfunction
- Heart disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Smoker subjects take 6 capsules once a day for 4 weeks.
|
|
Experimental: Aged garlic extract
Smoker subjects take 1.5 g of aged garlic extract in 6 capsules once a day for 4 weeks.
|
|
No Intervention: Non-smoker
Oxidative status in non-smoker
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Urinary 8-hydroxydeoxyguanosine (8-OHdG)
Time Frame: Every 4 weeks (Overall 12 weeks)
|
Every 4 weeks (Overall 12 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
High sensitive CRP
Time Frame: Every 4 weeks (Overall 12 weeks)
|
Every 4 weeks (Overall 12 weeks)
|
Blood pressure
Time Frame: Every 4 weeks (Overall 12 weeks)
|
Every 4 weeks (Overall 12 weeks)
|
Indices of the second derivative of photoplethysmogram (SDPTG)
Time Frame: Every 4 weeks (Overall 12 weeks)
|
Every 4 weeks (Overall 12 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Actual)
April 1, 2015
Study Completion (Actual)
April 1, 2015
Study Registration Dates
First Submitted
December 18, 2013
First Submitted That Met QC Criteria
December 18, 2013
First Posted (Estimate)
December 24, 2013
Study Record Updates
Last Update Posted (Estimate)
August 19, 2015
Last Update Submitted That Met QC Criteria
August 17, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Other Study ID Numbers
- eki-843
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heavy Smoker or Non-smoker
-
Scott Kollins, PhDNational Institute on Drug Abuse (NIDA)CompletedADHD | Non-smokerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCurrent Smoker | Cigarette Smoker | Currently Living With SmokerUnited States
-
Roswell Park Cancer InstituteNational Institute on Drug Abuse (NIDA); National Cancer Institute (NCI)CompletedCurrent Smoker | Healthy Subject | Cigarette SmokerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCurrent Every Day Smoker | Cigarette SmokerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCurrent Every Day Smoker | Cigarette SmokerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnCurrent Smoker | Malignant Neoplasm | Current Every Day Smoker | Cigarette SmokerUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Drug Abuse (NIDA)RecruitingCurrent Every Day Smoker | Cigarette SmokerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCurrent Every Day Smoker | Cigarette SmokerUnited States
-
M.D. Anderson Cancer CenterNational Institute on Drug Abuse (NIDA); National Cancer Institute (NCI)CompletedCurrent Every Day Smoker | Cigarette Smoker | StudentUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingCurrent Smoker | Current Every Day Smoker | Cigarette SmokerUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States